ViaCyte raises fund to develop diabetes treatment

July 10
9:20 AM 2013

ViaCyte announced on Wednesday that it has raised a total of US$10.6 million in Series C-1 funding. Several big names participated in the round, including Johnson & Johnson Development Corp., Asset Management Company or Johnson Trust, and Sanderling Ventures.

ViaCyte is a cell therapy development firm, focusing of the treatment of diabetes. The company is headquartered in Atlanta, Georgia.

The fund raised matched the company's previous US$10.1 million grant approval by the California Institute of Regenerative Medicine last October. This award was given to the company in support of the research and development of the VC-01, an enterprise of ViaCyte which is used as transformative therapy to Type 1 and Insulin Type 2 diabetes patients.

The company also has the option to sell more Series C-1 Preferred Stock shares.

Commenting on the fundraiser, ViaCyte President Paul Laikind, Ph.D., said "The success of VC-01 will validate ViaCyte's proprietary, stem cell-derived cell therapy platform that has multiple applications, as well as demonstrate the full utility of the Company's encapsulation technology for enabling allogeneic cell therapy treatments."

© 2022 VCPOST, All rights reserved. Do not reproduce without permission.


Join the Conversation

Subscribe to VCpost newsletter

Sign up for our Deals of the Day newsletter.
We will not spam you!

Real Time Analytics